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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: Folic acid deficiency (FAD) may result in macrocytic anemia. This study
assessed the hematinic deficiencies and anemia statuses in oral mucosal disease patients with
FAD (defined as folic acid  6 ng/mL).
Methods: The blood hemoglobin (Hb), iron, vitamin B12, and folic acid concentrations, serum
gastric parietal cell antibody level, and mean corpuscular volume (MCV) in 198 oral mucosal
disease patients with FAD were measured. Based on World Health Organization (WHO) criteria,
anemia or Hb deficiency was defined as having an Hb concentration of <13 g/dL for men and
<12 g/dL for women. In this study, macrocytic anemia due to FAD was defined as having an
MCV 100 fL and folic acid 6 ng/mL; pernicious anemia as having MCV 100 fL, vitamin
B12 < 200 pg/mL, and serum gastric parietal cell antibody positivity; iron deficiency anemia
as having MCV <80 fL and iron <60 mg/dL; and thalassemia trait as having MCV <74 fL, red
blood cell (RBC) count > 5.0  1012/L, and Mentzer index (MCV/RBC) < 13.
Results: We found that by WHO definitions, 73 (36.9%), 41 (20.7%), and 10 (5.1%) of our 198 FAD
patients had concomitant Hb, iron, and vitamin B12 deficiencies, respectively. Of 73 anemic
FAD patients, three had macrocytic anemia due to FAD, one had pernicious anemia, 14 had iron
deficiency anemia, eight had thalassemia trait, and the resting 47 had normocytic anemia.
Conclusion: In addition to macrocytic anemia (2.0%), FAD patients may have concomitant nor-
mocytic (23.7%) or microcytic (11.1%) anemia.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.have no conflicts of interest relevant to this article.
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Anemia in folic acid deficiency patients 807IntroductionFolic acid is an important B vitamin that is necessary for
DNA synthesis of red blood cells (RBCs). Folic acid defi-
ciency (FAD) may result in macrocytosis that is defined as
having a mean corpuscular volume (MCV)  100 fL.1e3 Pa-
tients with FAD or macrocytosis may or may not have ane-
mia. FAD results from poor nutritional intake,
malabsorption, hepatobiliary dysfunction, increased folate
catabolism, and medication (e.g., methotrexate, 5-
fluorouracil, phenytoin).2 Moreover, the etiologies of
macrocytic anemia include nutritional deficiencies (vitamin
B12 and folic acid), drugs (e.g., chemotherapeutic, antire-
troviral, and antimicrobial agents), primary bone marrow
disorders (e.g., myelodysplasia and leukemia), and other
chronic illness (such as alcoholism and hypothyroidism).1e3
Because multiple causes are involved in FAD and macrocy-
tosis, it is interesting to know the frequency of macrocy-
tosis or macrocytic anemia in oral mucosal disease patients
with FAD.
In our oral mucosal disease clinic, there are many pa-
tients with burning mouth syndrome (BMS), atrophic glos-
sitis (AG), recurrent aphthous ulcerations (RAUs), or oral
lichen planus (OLP). For these patients, complete blood
count and examination of serum iron, vitamin B12, folic
acid, and homocysteine levels are usually ordered to check
whether these patients have microcytic, normocytic, or
macrocytic anemia, thalassemia, and deficiencies of hem-
atinics.4e16 If patients with oral mucosal disease have he-
matinic deficiencies, multiple hematinic supplement
therapy frequently results in correction of anemic status
and improvement of oral symptoms and signs.15,16 Although
not often encountered, patients with FAD (defined as hav-
ing a serum folic acid level  6 ng/mL in this study)
sometimes show up at our clinic. In this study, 198 oral
mucosal disease patients with FAD were enrolled from the
oral mucosal disease clinic of National Taiwan University
Hospital (NTUH). Their oral manifestations (including
burning sensation and numbness of oral mucosa, dry mouth,
dysfunction of taste), specific oral mucosal diseases (such
as BMS, AG, RAU, and OLP), MCV, and blood levels of he-
moglobin (Hb), iron, vitamin B12, folic acid, and homocys-
teine were inquired, examined, and recorded. These data
were compared with the corresponding data of 198 age-
and sex-matched healthy control participants without oral
mucosal and systemic diseases to observe the frequencies
of FAD in different types of patients with BMS, RAU, AG, or
OLP and to assess whether FAD patients had higher fre-
quencies of anemia, other hematinic deficiencies, abnor-
mally high blood homocysteine level, high MCV (100 fL),
low MCV (<80 fL), gastric parietal cell antibody (GPCA)
positivity, and specific oral manifestations compared with
healthy control participants.
Materials and methods
Patients
In this study, oral mucosal disease patients with FAD were
defined as having a serum folic acid 6 ng/mL. This folic
acid concentration was chosen because it was the cutoffpoint concentration for giving folic acid supplement treat-
ment to FAD patients in our previous studies.15,16 Based on
the above selected concentration for FAD, 198 oral mucosal
disease patients (80 men and 118 women, age range 21e85
years, mean 54.5  14.1 years) with FAD were recruited.
For each patient, one age- (2 years of each patient’s age)
and sex-matched healthy control participant was selected.
Thus, the normal control group consisted of 198 healthy
control participants (80 men and 118 women, age range
20e84 years, mean 55.6  13.6 years). All the patients and
healthy control participants were seen consecutively,
diagnosed, treated, and selected in the oral mucosal dis-
ease clinic of NTUH from July 2007 to March 2015. The 198
oral mucosal disease patients with FAD had one or two of
the oral diseases including BMS, AG, RAU, and OLP. BMS was
diagnosed when patients had a burning sensation of the oral
mucosa in the absence of clinically apparent mucosal al-
terations.4,15 Patients were diagnosed as having partial or
complete AG when their dorsal tongues showed partial or
complete absence or flattening of filiform papillae,
respectively.5,16 RAU was diagnosed when patients had at
least one episode of oral ulcerations per month during the
preceding years.6 OLP was diagnosed according to the
following criteria: (1) a typical clinical presentation of
radiating grayish-white Wickham striae or papules (non-
erosive OLP) combined with erosion or ulceration on the
bilateral buccal or vestibular mucosa (erosive OLP); and (2)
biopsy specimens characteristic of OLPdthat is, hyperker-
atosis or parakeratosis, a slightly acanthotic epithelium
with liquefaction degeneration of the basal epithelial cells,
a pronounced band-like lymphocytic infiltrate in the lamina
propria, and the absence of epithelial dysplasia.7,8 How-
ever, all FAD patients with areca quid chewing habit,
autoimmune diseases (such as systemic lupus erythemato-
sus, rheumatoid arthritis, Sjogren’s syndrome, pemphigus
vulgaris, and cicatricial pemphigoid), inflammatory dis-
eases, malignancy, or recent surgery were excluded. In
addition, all FAD patients with serum creatinine concen-
trations indicative of renal dysfunction (i.e., men, >131mM;
women, >115mM), and who reported a history of stroke,
heavy alcohol use, or diseases of the liver, kidney, or cor-
onary arteries were also excluded.17 Healthy control par-
ticipants had either dental caries, pulpal disease,
malocclusion, or missing teeth but did not have any oral
mucosal or systemic diseases. None of our FAD patients had
taken any prescription medication for malignancies, epi-
lepsy, diabetes mellitus, infection, inflammation, BMS, AG,
RAU, or OLP at least 3 months prior to entering the study.
According to the aforementioned diagnostic criteria, 198
oral mucosal disease patients with FAD retrieved from 77 of
847 BMS patients, 62 of 826 AG patients, 33 (8 also had AG
and 4 also had BMS) of 306 RAU patients, and 26 (9 also had
AG) of 336 OLP patients were included in this study. For all
FAD patients and healthy control participants, oral mani-
festations including burning sensation and numbness of oral
mucosa, dry mouth, dysfunction of taste, AG, RAU, and OLP
were inquired, examined, and recorded. The blood samples
were drawn from all patients and healthy control partici-
pants for measurement of complete blood count, blood
iron, vitamin B12, folic acid, and homocysteine concentra-
tions as well as serum GPCA levels. All patients and healthy
control participants signed an informed consent form prior
808 J.Y.-F. Chang et al.to entering the study. This study was reviewed and
approved by the Institutional Review Board at the NTUH.
Determination of complete blood count and blood
iron, vitamin B12, folic acid, and homocysteine
concentrations
The complete blood count and blood iron, vitamin B12, folic
acid, and homocysteine concentrations were determined
using routine tests performed in the Department of Labo-
ratory Medicine of NTUH as described previously.4e16
Determination of serum GPCA level
The serum GPCA level was detected using the indirect
immunofluorescence technique using rat stomach as a
substrate as described previously.5,12 In brief, 5-mm-thick
cryostat sections of substrate tissues on slides were reacted
with serially diluted patients’ and control participants’ sera
in a moist chamber at room temperature for 30 minutes.
The initial dilution of the patients’ and control partici-
pants’ sera was 1:20 with phosphate-buffered saline. After
washing, the sections were incubated with fluorescein
isothiocyanate-labeled goat antihuman IgG antiserum
(Boehringer Mannheim Biochemicals, Indianapolis, IN, USA),
which had been prediluted and kept in a dropper vial by the
manufacturer and was ready to use for another 30 minutes.
The sections were washed again, mounted with buffered
glycerine, and examined using an Olympus fluorescence
microscope (Olympus, Tokyo, Japan). Sera were scored as
positive when they produced fluorescence at a dilution of
20-fold or more.
Statistical analysis
Comparisons of the MCV and mean blood levels of Hb, iron,
vitamin B12, folic acid, and homocysteine between 198 oral
mucosal disease patients with FAD and 198 age- and sex-
matched healthy control participants were performed
using Student t test. The differences in frequency of Hb,Table 1 Mean corpuscular volume (MCV) and mean blood concen
homocysteine in 198 patients with folic acid deficiency (FAD; fol
control participants.
Factor FAD patients (n Z 198) H
Mean  SD Range Mea
MCV (fl) 87.5  9.3 58.6e136.8 90
Hb (g/dL)
Men (n Z 80) 14.0  1.5 10.1e16.7 15
Women (n Z 118) 12.3  1.5 8.2e15.2 13
Iron (mg/dL)
Men (n Z 80) 93.9  30.7 18.0e183.0 103
Women (n Z 118) 84.7  39.6 14.0e239.0 97
Vitamin B12 (pg/mL) 574.7  265.2 150.0e1000.0 643
Folic acid (ng/mL) 4.7  1.0 1.6e5.9 13
Homocysteine (mM) 11.6  6.7 3.9e70.1 8
*Comparison of the MCV and mean blood levels of Hb, iron, vitamin B1
age- and sex-matched healthy control participants using Student t teiron, vitamin B12, or folic acid deficiency, of abnormally
high blood homocysteine level, or of GPCA positivity be-
tween 198 FAD patients and 198 age- and sex-matched
healthy control participants were compared using chi-
square test. Comparisons of MCV, mean blood concentra-
tions of Hb, iron, vitamin B12, folic acid, and homocysteine,
and GPCA positivity between any two of the three groups of
patients with macrocytic, normocytic, or microcytic RBCs
were performed using Student t test or chi-square test,
where appropriate. In addition, the differences in fre-
quency of each oral manifestation between 198 oral
mucosal disease patients with FAD and 198 age- and sex-
matched healthy control participants were also compared
using chi-square test. The result was considered to be sig-
nificant if the p value was less than 0.05.Results
The MCV and mean blood concentrations of Hb, iron,
vitamin B12, folic acid, and homocysteine in 198 oral
mucosal disease patients with FAD and in 198 age- and sex-
matched healthy control participants are shown in Table 1.
Because men usually had higher blood levels of Hb and iron
than women, these two mean levels were calculated
separately for men and women. We found significantly
lower mean MCV (p < 0.001), Hb (for both men and women,
both p < 0.001), iron (for both men and women; men,
pZ 0.008 and women, pZ 0.005), vitamin B12 (pZ 0.005),
and folic acid (p < 0.001) levels as well as significantly
higher mean blood homocysteine level (p < 0.001) in oral
mucosal disease patients with FAD than in healthy control
participants (Table 1).
According to the World Health Organization (WHO)
criteria, men with Hb < 13 g/dL and women with
Hb < 12 g/dL were defined as having Hb deficiency or
anemia.18 Furthermore, patients with serum iron
level < 60 mg/dL19 or serum vitamin B12 level < 200 pg/mL
17
were defined as having iron or vitamin B12 deficiency,
respectively. As stated before, patients with a serum folic
acid level 6 ng/mL was defined as having FAD in thistrations of hemoglobin (Hb), iron, vitamin B12, folic acid, and
ic acid  6 ng/dL) and in 198 age- and sex-matched healthy
ealthy control participants (n Z 198) p (Student t test)
n  SD Range
.6  3.4 80.0e98.6 <0.001*
.1  0.7 13.6e16.6 <0.001*
.6  0.7 12.2e15.2 <0.001*
.8  26.6 62.0e187.0 0.008*
.0  26.5 60.0e204.0 0.005*
.8  222.9 259.0e1000.0 0.005*
.4  5.6 4.1e24.0 <0.001*
.8  2.0 4.3e13.4 <0.001*
2, folic acid, and homocysteine between 198 FAD patients and 198
st with p < 0.01. SD Z standard deviation.
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level >12.8 mM (which was the mean blood homocysteine
level of healthy control participants plus 2 standard de-
viations) were defined as having abnormally high homo-
cysteine level. Based on the above-mentioned definitions,
73 (36.9%), 41 (20.7%), and 10 (5.1%) of 198 oral mucosal
disease patients with FAD had concomitant Hb, iron, and
vitamin B12 deficiencies, respectively. Moreover, 64 (32.3%)
and 19 (9.6%) of our 198 FAD patients had abnormally high
blood homocysteine levels (>12.8 mM) and serum GPCA
positivity, respectively (Table 2). However, none of the
normal control participants were diagnosed as having Hb,
iron, and vitamin B12 deficiencies based on the aforemen-
tioned strict WHO criteria. However, FAD was found in 11
(5.6%) of normal control participants. FAD patients had a
significantly higher frequency of Hb, iron, vitamin B12, or
folic acid deficiency, of abnormally high blood homocyste-
ine level, and of GPCA positivity than healthy control par-
ticipants (all p < 0.001 except for vitamin B12 deficiency,
p Z 0.004) (Table 2).
In this study, 73 (36.9%) FAD patients were diagnosed as
having anemia according to the WHO criteria.18 If macro-
cytic anemia due to FAD was defined as having an
MCV  100 fL and folic acid  6 ng/mL; pernicious anemia
as having MCV  100 fL, vitamin B12 < 200 pg/mL, and
serum GPCA positivity; iron deficiency anemia as having
MCV < 80 fL and iron < 60 mg/dL; and thalassemia trait as
having MCV < 74 fL, RBC count > 5.0  1012/L, and Mentzer
index (MCV/RBC) < 13, we found that of the 73 anemic FAD
patients, three had macrocytic anemia due to FAD, one had
pernicious anemia, 14 had iron deficiency anemia, eight
had thalassemia trait, and the resting 47 patients had
normocytic anemia.
When 198 FAD patients were further divided into Group 1
(8 patients with MCV  100 fL), Group 2 (159 patients with
MCV between 80 and 99.9 fL), and Group 3 (31 patients with
MCV < 80 fL), we found that Group 1 patients had signifi-
cantly higher MCV (p< 0.001), higher mean serum iron level
(for women only, p < 0.001), higher mean serum homo-
cysteine level (p Z 0.001), and higher frequency of serum
GPCA positivity (p Z 0.024) than Group 2 patientsTable 2 Number and percentage of individuals with hemoglobi
high homocysteine level, or with serum gastric parietal cell antibo
(FAD; folic acid  6 ng/dL) and in 198 age- and sex-matched hea
Factor No
FAD patients
(n Z 198)
Hemoglobin deficiency (men, <13 g/dL;
women, <12 g/dL)
73 (36.9)
Iron deficiency (<60 mg/dL) 41 (20.7)
Vitamin B12 deficiency (<200 pg/mL) 10 (5.1)
Folic acid deficiency (6 ng/mL) 198 (100.0)
High homocysteine level (>12.8 mM)a 64 (32.3)
GPCA positivity 19 (9.6)
*Comparison of frequency of hemoglobin, iron, vitamin B12, or folic ac
GPCA positivity between 198 FAD patients and 198 age- and sex-matc
a High homocysteine level was defined as patients with a homocys
healthy control participants plus 2 standard deviations.(Table 3). Moreover, Group 3 patients had a significantly
lower mean Hb level (for men, p Z 0.002; for women,
p < 0.001), lower MCV (p < 0.001), and lower mean serum
iron level (for women only, p < 0.001) than Group 2 pa-
tients (Table 3). In addition, Group 1 patients had a
significantly higher MCV (p < 0.001), higher mean serum
iron level (for women only, p Z 0.001), and higher mean
serum homocysteine level (p Z 0.041) than Group 3 pa-
tients (Table 3).
The oral manifestations in 198 oral mucosal disease pa-
tients with FAD and in 198 healthy control participants are
shown in Table 4. We found that oral mucosal disease pa-
tients with FAD had significantly higher frequencies of all
oral manifestations than healthy control participants (all
p < 0.001), in which burning sensation of oral mucosa
(72.2%), AG (39.9%), and dry mouth (35.4%) were the three
leading oral manifestations for FAD patients (Table 4).Discussion
This study found that of the 198 FAD patients, eight had
macrocytic RBCs, 31 had microcytic RBCs, and 159 had
normocytic RBCs. Moreover, 73 (36.9%) of the 198 FAD pa-
tients had anemia (men with Hb < 13 g/dL and women with
Hb < 12 g/dL). Of the 73 anemic FAD patients, four had
macrocytic anemia (MCV  100 fL; including 3 with
macrocytic anemia due to FAD and 1 with pernicious ane-
mia), 22 had microcytic anemia (MCV < 80 fL; including 14
with iron deficiency anemia and 8 with thalassemia trait),
and 47 had normocytic anemia (MCV between 80 fL and
99.9 fL). Of the 47 FAD patients with normocytic anemia, 10
had concomitant iron deficiency (iron < 60 mg/dL), 15 had
concomitant relative iron deficiency (60 mg/
dL < iron  80 mg/dL), one had concomitant vitamin B12
deficiency (vitamin B12 < 200 pg/mL), and the resting 22
had FAD only. Because FAD may cause macrocytic anemia,2
but iron deficiency may cause microcytic anemia,19 those
with both FAD and real or relative iron deficiency may have
normocytic anemia because of the neutralization effect.
Our findings indicate that FAD patients may haven, iron, vitamin B12, or folic acid deficiency, with abnormally
dy (GPCA) positivity in 198 patients with folic acid deficiency
lthy control participants.
. of participants (%) p (Chi-square test)
Healthy control
participants (n Z 198)
0 (0) <0.001*
0 (0) <0.001*
0 (0) 0.004*
11 (5.6) <0.001*
3 (1.5) <0.001*
3 (1.5) <0.001*
id deficiency, of abnormally high homocysteine level, or of serum
hed healthy control subjects by chi-square test with p < 0.05.
teine level greater than the mean of the homocysteine level of
Table 3 Mean corpuscular volume (MCV), mean blood concentrations of hemoglobin (Hb), iron, vitamin B12, folic acid, and
homocysteine, and gastric parietal cell antibody (GPCA) positivity in eight folic acid deficiency (FAD) patients with MCV  100 fL
(Group 1), in 159 FAD patients with MCV between 80 fL and 99.9 fL (Group 2), and in 31 FAD patients with MCV < 80 fL (Group 3).
Patients with folic acid deficiency (n Z 198)
Group 1
MCV  100 fL (n Z 8)
p* (Group 1
vs. Group 2)
Group 2
MCV 80e99.9 fL
(n Z 159)
p* (Group 2
vs. Group 3)
Group 3
MCV <80 fL
(n Z 31)
p* (Group 1
vs. Group 3)
Mean  SD Mean  SD Mean  SD
Hb (g/dL)
Men 13.9  1.5 (n Z 3) 0.718 14.2  1.4
(n Z 65)
0.002* 12.8  1.4
(n Z 12)
0.250
Women 11.6  2.0 (n Z 5) 0.106 12.6  1.3
(n Z 94)
<0.001* 11.1  1.3
(n Z 19)
0.501
MCV (fL) 107.7  11.9 <0.001* 89.7  4.1 <0.001* 71.2  6.1 <0.001*
Iron (mg/dL)
Men 83.0  37.0 (n Z 3) 0.421 97.0  29.0
(n Z 65)
0.124 82.0  39.0
(n Z 12)
0.969
Women 150.0  70.0 (n Z 5) <0.001* 87.0  32.0
(n Z 94)
<0.001* 58.0  43.0
(n Z 19)
0.001*
Vitamin B12 (pg/mL) 509.0  330.0 0.446 583.0  264.0 0.499 548.0  258.0 0.721
Folic acid (ng/mL) 4.7  1.4 > 0.99 4.7  1.0 0.606 4.8  0.9 0.805
Homocysteine (mM) 19.4  21.0 0.001* 11.4  5.3 0.564 10.8  5.2 0.041*
GPCA positivity 3 (37.5%) 0.024* 12 (7.5%) 0.529 4 (12.9%) 0.137
*Comparisons of MCV, mean blood concentrations of Hb, iron, vitamin B12, folic acid and homocysteine, and GPCA positivity between
Groups 1 and 2, between Groups 2 and 3, and between Groups 1 and 3 with p < 0.05 using Student t test or chi-square test, where
appropriate. SD Z standard deviation.
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(15.7%) RBCs. Furthermore, in addition to macrocytic ane-
mia (2.0%), FAD patients may have concomitant microcytic
(11.1%) or normocytic (23.7%) anemia.
Of the 10 FAD patients with vitamin B12 deficiency, only
four had serum GPCA positivity (i.e., the vitamin B12 defi-
ciency can be attributed to the presence of GPCA). Thus,
the vitamin B12 deficiency in the other six GPCA-negative
FAD patients may be attributable to other causes
including inadequate intake or malabsorption of vitamin
B12, the presence of anti-intrinsic factor antibodies, or
transcobalamin II deficiency.20Table 4 Oral manifestations in 198 patients with folic acid defi
matched healthy control participants.
Oral manifestation No. of par
FAD patients
(n Z 198)
Burning sensation 143 (72.2)
Atrophic glossitis 79 (39.9)
Dry mouth 70 (35.4)
Numbness 49 (24.7)
Recurrent aphthous
ulcerations
33 (16.7)
Oral lichen planus 26 (13.1)
Dysfunction of taste 23 (11.6)
*Comparison of frequency of each oral manifestation between 198 F
ticipants using chi-square test with p < 0.001.In this study, eight (4.0%) of 198 FAD patients had
macrocytosis. Of the eight macrocytosis patients, two had
concomitant vitamin B12 deficiency and GPCA positivity,
one had concomitant vitamin B12 and iron deficiencies and
GPCA positivity, one had concomitant iron deficiency, and
the resting four had FAD only. Because vitamin B12 and/or
folic acid deficiencies may result in the generation of
macrocytic RBCs,1e3 the causes of macrocytosis in our eight
FAD patients are probably due to vitamin B12 and/or folic
acid deficiencies.3
Homocysteine is a sulfur-containing amino acid formed
during methionine metabolism.21 Both vitamin B12 and folicciency (FAD; folic acid  6 ng/mL) and in 198 age- and sex-
ticipants (%) p (Chi-square
test)Healthy control
participants (n Z 198)
0 (0) <0.001*
0 (0) <0.001*
0 (0) <0.001*
0 (0) <0.001*
0 (0) <0.001*
0 (0) <0.001*
0 (0) <0.001*
AD patients and 198 age- and sex-matched healthy control par-
Anemia in folic acid deficiency patients 811acid act as coenzymes for the conversion of homocysteine
to methionine.22 Higher blood homocysteine levels can
cause oxidative stress, damage endothelium, and enhance
thrombogenicity in experimental studies, and thus are
associated with increased rates of coronary heart disease
and stroke.21,23e26 Moreover, measurement of both serum
methylmalonic acid and homocysteine levels is discovered
to be a more sensitive method of screening for vitamin B12
deficiency (with a sensitivity of 99.8%) and thus can be used
for detecting subclinical vitamin B12 deficiency.
20,27 In this
study, an abnormally higher blood homocysteine level was
detected in 64 (32.3%) of the 198 FAD patients but could be
found in only three (1.5%) of the 198 healthy control par-
ticipants. The high blood homocysteine level in patients is
found to be attributable to deficiencies in folic acid,
vitamin B12, and vitamin B6, because a supplement therapy
with folic acid, vitamin B12, and vitamin B6 to patients can
reduce blood homocysteine levels.15,16,23 In this study, all
64 patients with abnormally higher blood homocysteine
levels had FAD and nine FAD patients had concomitant
vitamin B12 deficiency. Moreover, our FAD patients also had
a significantly lower mean serum vitamin B12 or folic acid
level compared with healthy control participants. There-
fore, the high blood homocysteine level in our FAD patients
was due to FAD or both folic acid and vitamin B12
deficiencies.
This study showed significantly higher frequencies of all
oral manifestations in our oral mucosal disease patients
with FAD than in healthy control participants (all
p < 0.001). These oral manifestations included burning
sensation of oral mucosa (72.2%), AG (39.9%), dry mouth
(35.4%), numbness of oral mucosa (24.7%), RAU (16.7%),
OLP (13.1%), and dysfunction of taste (11.6%). Our previous
studies found burning sensation of oral mucosa, dry mouth,
numbness of oral mucosa, and dysfunction of taste in 100%,
75.7%, 43.9%, and 19.8% of 399 BMS patients, respectively4;
and in 100%, 79.0%, 57.4%, and 27.8% of 176 AG patients,
respectively.5 Because 81, 79, 33, and 26 of our 198 FAD
patients had concomitant BMS, AG, RAU, and OLP, this
could explain why our oral mucosal disease patients with
FAD had significantly higher frequencies of all oral mani-
festations including burning sensation of oral mucosa, dry
mouth, numbness of oral mucosa, and dysfunction of taste
than healthy control participants. In addition, 36.9% of our
198 FAD patients had anemia according to the WHO
criteria.18 Anemia patients have reduced hemoglobin
levels, which carries insufficient oxygen to oral mucosa,
and finally results in atrophy of oral mucosa.9 Moreover,
20.7% and 32.3% of our 198 FAD patients had concomitant
iron and vitamin B12 deficiencies, respectively. Iron is
essential to the normal functioning of oral epithelial cells,9
and both vitamin B12 and folic acid play important roles in
DNA synthesis and cell division.1e3,17,28 Oral epithelial cells
have a high turnover rate. Therefore, deficiencies of iron,
vitamin B12, and folic acid may result in oral epithelial at-
rophy. Furthermore, a high blood homocysteine level may
result in an elevated frequency of thrombosis in the feeding
arterioles that supply nutrients to the oral epithelial
cells.21,23e26 This, in turn, leads to oral epithelial atrophy.
Atrophic tongue dorsal or other oral mucosa in FAD patients
could partially explain why a significant number of our oral
mucosal disease patients with FAD had burning sensationand numbness of oral mucosa and dysfunction of taste.5
The reasons why BMS and AG patients may have burning
sensation and numbness of oral mucosa, dry mouth, and
dysfunction of taste compared with healthy control par-
ticipants have been explained in detail in our previous
studies.4,5
Our results demonstrated that 36.9%, 20.7%, and 5.1% of
our 198 oral mucosal disease patients with FAD had
concomitant Hb, iron, and vitamin B12 deficiencies by WHO
definitions, respectively. Moreover, 32.3% and 9.6% of our
198 FAD patients had abnormally high blood homocysteine
levels and serum GPCA positivity, respectively. We also
found a significantly higher frequency of Hb, iron, vitamin
B12, or folic acid deficiency, of abnormally high blood ho-
mocysteine levels, or of GPCA positivity in our 198 FAD
patients than in 198 healthy control participants. Of 73
anemic FAD patients, three had macrocytic anemia due to
FAD, one had pernicious anemia, 14 had iron deficiency
anemia, eight had thalassemia trait, and the resting 47 had
normocytic anemia. Our findings indicate that, in addition
to macrocytic anemia (2.0%), FAD patients may have
concomitant normocytic (23.7%) or microcytic (11.1%)
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